tradingkey.logo

Cartesian Therapeutics Inc <RNAC.OQ> expected to post a loss of 71 cents a share - Earnings Preview

ReutersMay 2, 2025 1:05 PM
  • Cartesian Therapeutics Inc RNAC.OQ RNAC.O is expected to show a fall in quarterly revenue when it reports results on May 6 (estimated) for the period ending March 31 2025

  • The Frederick Maryland-based company is expected to report a 86.5% decrease in revenue to $785.71 thousand from $5.84 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Cartesian Therapeutics Inc is for a loss of 71 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Cartesian Therapeutics Inc is $40.50​, above​ its last closing price of $12.27. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.87

-0.80

-0.59

Beat

26.3

Sep. 30 2024

-0.78

-0.79

-1.13

Missed

-42.7

Jun. 30 2024

-0.91

-1.07

0.54

Beat

150.6​

Mar. 31 2024

-0.80

-0.88

-10.50

Missed

-1,086.4

​​Dec. 31 2023

-0.60

-1.05

-2.10

Missed

-100

Sep. 30 2023

-1.34

-1.75

-1.80

Missed

-2.9​

Jun. 30 2023

-2.31

-2.40

-2.10

Beat

12.5

Mar. 31 2023

-2.62

-2.61

-4.20

Missed

-60.7

This summary was machine generated May 2 at 13:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI